As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001 ... with moderately severe to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback